PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.

pdx news

  • PDX Pharmaceuticals raised $4M ($1.5M first milestone payment) in November of 2019 to take its new HER2-targeted therapy to clinical trials.

    1/16/2020
    read more

  • PDX Pharma hosts delegates from the Japan Health Sciences Foundation

    11/1/2019
    read more

  • siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion

    10/9/2019
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved